Amoéba

AGM Information • Dec 28, 2018

PRESS RELEASE

Chassieu, 28th December 2018

ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 14th JANUARY 2019

MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

The company's shareholders are invited to attend the ordinary and extraordinary annual general meetings which will be held on:

Monday 14th January 2019 – 10 am

At the company registered office - 38 Avenue des Frères Montgolfier- 69680 CHASSIEU

The notice of the meeting, including the agenda and the planned resolutions, was published in the BALO (Bulletin of obligatory legal announcements) of 7 th December 2018; the notice convening the meeting was published in the BALO of 28th December 2018.

The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:

• Any named shareholder can, until the fifth day (inclusive) before the assembly, ask the company to send them these documents. For holders of bearer shares, this right can only be exercised upon presentation of a statement of participation in the accounts of bearer shares held by the authorised intermediary;
• Any shareholder can consult these documents at the company's headquarters during the 15 days preceding the date of the assembly.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4) . In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

• (2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets
• (3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba Valérie FILIATRE Directeur administratif et Financier 04 26 69 16 00 valerie.filiatre@amoeba-biocide.com Actifin

Ghislaine GASPARETTO Communication financière 01 56 88 11 11 ggasparetto@actifin.fr